A 24-week, Multi-center, Open-label Evaluation of Compliance and Tolerability of the Once-daily 10 cm² Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.
A 24-week, Multi-center, Open-label Evaluation of Compliance and Tolerability of the Once-daily 10 cm² Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a cholinesterase inhibitor, and in patients who were unresponsive to previous cholinesterase inhibitor treatment in a community setting.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Chemside, Queensland 4032, Australia
Kuala Lumpur, Selangor 50586, Malaysia
Bundang, Seongnam 463-707, South Korea
Atakum / Samsun, 55139, Turkey (Türkiye)
Emek / Ankara, 06510, Turkey (Türkiye)
Etlik / Ankara, 06018, Turkey (Türkiye)
Meselik / Eskisehir, 26480, Turkey (Türkiye)
Talas / Kayseri, 38039, Turkey (Türkiye)
Uskudar / Istanbul, 34668, Turkey (Türkiye)